Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Item
http://www.wikidata.org/entity/Q37741534
Current progress in innovative engineered antibodies.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.Enhanced Therapeutic Activity of Non-Internalizing Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination With Targeted Interleukin-2.89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.
P2860

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Item
http://www.wikidata.org/entity/Q37741534
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cergutuzumab amunaleukin (CEA- ...... al IL-2-based immunocytokines.
@en
Cergutuzumab amunaleukin (CEA- ...... al IL-2-based immunocytokines.
@nl
type
label
Cergutuzumab amunaleukin (CEA- ...... al IL-2-based immunocytokines.
@en
Cergutuzumab amunaleukin (CEA- ...... al IL-2-based immunocytokines.
@nl
prefLabel
Cergutuzumab amunaleukin (CEA- ...... al IL-2-based immunocytokines.
@en
Cergutuzumab amunaleukin (CEA- ...... al IL-2-based immunocytokines.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Cergutuzumab amunaleukin (CEA- ...... nal IL-2-based immunocytokines
@en
P2093
P2860
P304
P31
P356
10.1080/2162402X.2016.1277306
P433
P478
P50
P577
P698
P921
P932